Day: May 9, 2022

EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent HighlightsDelivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over yearSigned a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company’s Beacon® platform and proprietary high-throughput, functional screening serviceReleased an upgrade to the Software Suite for Beacon and Lightning® platforms, enabling customers to gain easier insights and faster throughput operations for antibody discovery, cell line development and cell therapy workflowsAppointed Siddhartha Kadia as chief executive officer (CEO) and Lucas Vitale as chief human resources...

Q1 2022 Revenue Increased 20.1% and Shipments Increased 15.3% vs. Q4 2021 NASHVILLE, Tenn., May 09, 2022 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced its financial results for the first quarter ended March 31, 2022. Revenue for the first quarter of 2022 increased 20.1% compared to the fourth quarter of 2021 with gross profit up 32.5% for the same period. First Quarter 2022 Financial HighlightsTotal revenue of $152 million, a 20.1% increase over the fourth quarter of 2021 and a decrease of 24.0% over the prior year period. Net loss of $(73) million, an improvement of $22 million over both the fourth quarter of 2021 and the prior year period. Adjusted EBITDA of $(34) million, a $27 million improvement over...

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering $15M milestone payment to Cara Top-line data from Phase 2 proof-of-concept trial of Oral KORSUVA (difelikefalin) in notalgia paresthetica expected in 2Q 2022 Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis underway Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 09, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended March 31, 2022. Manny Krakaris, Chief Executive Officer of Augmedix, commented, “We are pleased with our start to 2022 as we continue to make meaningful progress on several growth-focused initiatives, as well as extending our relationships with existing customers. Our main focus has been and will continue to be a path towards a completely automated note, and we have made great strides in this respect. We look forward to building upon the groundwork we have laid out to drive additional growth and gross margin expansion. We are excited for what is in store for the remainder of the year and optimistic that Augmedix will continue...

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022 Epilepsy Day showcases largest targeted epilepsy portfolio in industry Cash and investments of $222.5 million as of March 31, 2022 supports runway into 3Q23 BOSTON, May 09, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the first quarter 2022. “This...

First Quarter Highlights:Total revenue of $430.6 million, an increase of 151% year-over-year GAAP operating income of $26.7 million; non-GAAP operating income of $62.2 million GAAP consolidated net income of $18.8 million; non-GAAP consolidated net income of $48.9 million GAAP net loss attributable to common stockholders of ($62.1) million; non-GAAP net income attributable to common stockholders of $42.9 million Cash, cash equivalents and short-term investments of $375.0 million and no debt Consolidated Adjusted EBITDA of $65.7 million; Adjusted EBITDA of $58.0 millionCAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), a multinational, online automotive platform for buying and selling vehicles, today announced financial results for the first quarter ended March 31, 2022. “2022 is off to a...

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitisIndependent Data Monitoring Committee (DMC) recommends advancing to Phase 3Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pouchitis patients, the first of four important AMT-101 Phase 2 readouts,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT....

DELRAY BEACH, Fla., May 09, 2022 (GLOBE NEWSWIRE) — PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter and fiscal year ended March 31, 2022. Net sales for the quarter ended March 31, 2022, were $66.0 million, compared to $71.7 million for the comparable quarter in the prior year, representing a decrease of 7.9%. Net income of $6.1 million, or $0.30 diluted earnings per share, for the quarter ended March 31, 2022, declined 11% from net income of $6.8 million, or $0.34 diluted earnings per share, for the prior year quarter ended March 31, 2021. Adjusted EBITDA (1) was $9.5 million, or $0.47 diluted per share, for the current year quarter, compared to adjusted EBITDA of $10.4 million, or $0.52 diluted per share, for the quarter ended March 31, 2021. Net sales for the fiscal year ended March 31,...

ALLEN, Texas, May 09, 2022 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2022. Revenues for the first quarter of 2022 totaled $47.1 million compared to $39.2 million for the same period in 2021. For the quarter ended March 31, 2022, operating income was $10.3 million, up $1.3 million over the comparable 2021 period, and net income was $8.5 million, up $800 thousand over the same period in 2021. First quarter 2022 diluted earnings per share were $4.71 compared to $4.22 for the first quarter of 2021. Commenting on the results for the first quarter of 2022 compared to the prior year period, David Battat, President and CEO, stated, “Revenues were up 20% and operating income was up 15%, despite the impact of the pandemic and higher costs due to supply and labor...

Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD. Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, May 9th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) —  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology...